Preview Mode Links will not work in preview mode

Keeping Current CME

Oct 26, 2022

Newer oral glucose-lowering agents have revolutionized the treatment of type 2 diabetes (T2D), yet up to 40% of people across the globe still require insulin.

Credit available for this activity expires: 10/18/2023
Earn Credit / Learning Objectives & Disclosures: